Our findings in NPD subjects are consistent with those reported in a previous open-label study assessing the combination of liraglutide – a glucagon-like peptide-1 analog (1.2 mg QID) – plus metformin (1,000 mg BID) for 3 months in 36 women with polycystic ovary syndrome, of whom only 33% had impaired glucose tolerance. The gene discussed is GCG; the disease is polycystic ovary syndrome.